Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Common Equity (2020 - 2025)

Historic Common Equity for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $92.7 million.

  • Pulse Biosciences' Common Equity rose 1713.99% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 1713.99%. This contributed to the annual value of $114.9 million for FY2024, which is 15893.15% up from last year.
  • Latest data reveals that Pulse Biosciences reported Common Equity of $92.7 million as of Q3 2025, which was up 1713.99% from $104.5 million recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Common Equity registered a high of $118.5 million during Q1 2025, and its lowest value of -$10.7 million during Q1 2023.
  • For the 5-year period, Pulse Biosciences' Common Equity averaged around $49.4 million, with its median value being $44.4 million (2021).
  • Over the last 5 years, Pulse Biosciences' Common Equity had its largest YoY gain of 207330.96% in 2023, and its largest YoY loss of 15129.83% in 2023.
  • Over the past 5 years, Pulse Biosciences' Common Equity (Quarter) stood at $44.4 million in 2021, then crashed by 105.07% to -$2.2 million in 2022, then surged by 2073.31% to $44.4 million in 2023, then soared by 158.93% to $114.9 million in 2024, then dropped by 19.3% to $92.7 million in 2025.
  • Its Common Equity was $92.7 million in Q3 2025, compared to $104.5 million in Q2 2025 and $118.5 million in Q1 2025.